Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Financings

Ventripoint to Issue Shares for Payment of Debenture Interest

By The Northwire Desk — AI Analysis Dec 17, 2025 · 21:19 VPT · 0.115 VentriPoint Diagnostics Ltd.
VPT · Price

Executive Summary

  • Ventripoint Diagnostics Ltd. will satisfy $103,106.29 of accrued interest on multiple convertible debentures by issuing 1,145,627 common shares at a deemed price of $0.089 per share, subject to TSX Venture Exchange approval.
  • The issued shares are subject to a hold period of four months and one day and will not result in any party obtaining control of the corporation.
  • This transaction converts interest obligations into equity, preserving cash while modestly diluting existing shareholders.

Key Details

  • Interest Paid: $103,106.29 accrued on convertible debentures issued on May 10 2024; June 28 2024; September 20 2024; January 17 2025; February 7 2025; March 21 2025.
  • Shares Issued: 1,145,627 common shares to be issued as consideration for the interest payment.
  • Deemed Share Price: $0.089 per share (subject to TSXV approval).
  • Hold Period: Shares subject to a lock‑up of four months and one day from issuance.
  • Control Impact: The issuance will not create a control person under TSX Venture Exchange rules.
  • Interest Rate on Debentures: 10% per annum, payable semi‑annually.

Notable Quotes

(No executive quotes were included in the release.)

Read the original news release →

More from VentriPoint Diagnostics Ltd.

Jun 26, 2026 · 08:10

AI cardiac imaging startup scaling niche partnerships while navigating a critical $55k cash balance and negative working capital.

M&A / Property Jun 16, 2026 · 09:11

AI cardiac imaging startup scales commercial partnerships but remains cash-constrained and pre-revenue at scale.

Other Apr 28, 2026 · 08:00

Ventripoint Advances China Entry Amidst Persistent Dilution Concerns

Regulatory Apr 20, 2026 · 08:50

Ventripoint Wins Gold Edison Award But Cash Burn and Dilution Risks Persist

Other Apr 16, 2026 · 11:00

TSXV Venture Exchange Listed Cardiac Imaging Platform

M&A / Property Apr 01, 2026 · 22:50

Ventripoint Diagnostics Announces Collaboration with the Health Division of the Montecristo Group

M&A / Property